Medplus Health Services Limited
MEDPLUS · Hospitals · NSE
₹859
Current Market Price
Fair Value (DCF)
₹668
Discount to FV
-22.2%
Updated just now
YieldIQ Score
28/100
Piotroski F-Score
4/9
Economic Moat
None
Confidence
31%
ROE
11.1%
Debt/Equity
0.72
WACC
9.8%
Market Cap
₹10,321 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
20.0%
Return on capital employed
EV / EBITDA
19.0×
Enterprise multiple
Debt / EBITDA
1.8×
Leverage vs earnings
Interest Coverage
2.8×
EBIT covers interest
Current Ratio
3.20×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
4.6%
3-year revenue growth
Revenue CAGR (5Y)
11.2%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹859.45
Bear case
Discount -97.7%
Base case
Discount -28.6%
Bull case
Discount +16.8%
Ratio Trends
MEDPLUS · last 5 annual periods
ROE
11.1%
ROCE
20.0%
Operating Margin
—
Debt / Equity
0.72×
PE
156.8×
EV / EBITDA
27.1×
Historical Financials
MEDPLUS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹3755 Cr | ₹4529 Cr | ₹5574 Cr | ₹6136 Cr | ₹6892 Cr | +16.4% |
| EBITDA | ₹304 Cr | ₹312 Cr | ₹394 Cr | ₹536 Cr | ₹679 Cr | +22.3% |
| EBIT | ₹184 Cr | ₹130 Cr | ₹170 Cr | — | — | -2.0% |
| PAT | ₹95.8 Cr | ₹49.8 Cr | ₹65.5 Cr | ₹150 Cr | ₹220 Cr | +23.1% |
| EPS (diluted) | ₹8.52 | ₹4.17 | ₹5.45 | — | — | -10.6% |
| CFO | ₹170 Cr | ₹90.4 Cr | ₹144 Cr | ₹540 Cr | ₹496 Cr | +30.7% |
| CapEx | ₹-118 Cr | ₹-169 Cr | ₹-84.4 Cr | ₹-59.5 Cr | ₹-123 Cr | — |
| FCF | ₹52.2 Cr | ₹-78.6 Cr | ₹59.3 Cr | ₹481 Cr | ₹373 Cr | +63.5% |
| Total Assets | ₹2594 Cr | ₹2797 Cr | ₹3005 Cr | ₹3360 Cr | ₹3933 Cr | +11.0% |
| Total Debt | ₹815 Cr | ₹900 Cr | ₹1010 Cr | ₹1120 Cr | ₹1424 Cr | +15.0% |
| Shareholders' Equity | ₹1418 Cr | ₹1491 Cr | ₹1578 Cr | ₹1741 Cr | ₹1975 Cr | +8.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
MEDPLUS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
SANOFICONR SANOFICONR | — | — | Pending | 62.5% | — |
 VIJAYA VIJAYA | — | — | Pending | 17.9% | — |
 CONCORDBIO CONCORDBIO | — | — | Pending | 20.5% | — |
 METROPOLIS METROPOLIS | — | — | Pending | 12.6% | — |
INDGN INDGN | — | — | Pending | 12.8% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for MEDPLUS in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Medplus Health Services Limited (MEDPLUS.NS) trades at 859.45 vs a model fair value of 668.35, a gap of -22.2%. Piotroski F-score: 4/9. M...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of MEDPLUS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for MEDPLUS →
Compare
Head-to-head with peers
Compare MEDPLUS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse MEDPLUSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.